MAZ promotes thyroid cancer progression by driving transcriptional reprogram and enhancing ERK1/2 activation

被引:2
|
作者
Zeng, Jiajia [1 ,2 ]
Zhang, Long [1 ]
Huang, Linying [1 ]
Yu, Xinyuan [1 ]
Han, Linyu [1 ]
Zheng, Yanxiu [1 ]
Wang, Teng [3 ]
Zhang, Nasha [4 ,5 ]
Yang, Ming [1 ,2 ,3 ,5 ]
机构
[1] Shandong Canc Hosp & Inst, Canc Res Ctr, Shandong Prov Key Lab Precis Oncol, Jinan 250117, Shandong Provin, Peoples R China
[2] Shandong First Med Univ & Shandong Acad Med Sci, Sch Life Sci, Tai An, Shandong Provin, Peoples R China
[3] Shandong Univ, Canc Ctr, Jinan, Shandong Provin, Peoples R China
[4] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Shandong Provin, Peoples R China
[5] Nanjing Med Univ, Collaborat Innovat Ctr Canc Personalized Med, Jiangsu Key Lab Canc Biomarkers Prevent & Treatmen, Nanjing, Jiangsu Provinc, Peoples R China
基金
中国国家自然科学基金;
关键词
MAZ; BRAF; KRAS; LOC547; Thyroid cancer; ERK; GROWTH;
D O I
10.1016/j.canlet.2024.217201
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Papillary thyroid carcinoma (PTC) is the most common type of thyroid malignancies worldwide. Oncogenic transcription factors (TFs) drive transcriptional reprogramming and tumorigenesis. The myc-associated zinc finger protein (MAZ) is one of the Myc family TFs. The role of MAZ in PTC pathogenesis is still largely unknown. Here, we report that MAZ profoundly promotes proliferation of PTC cells ex vivo and in vivo through activating MAPK signaling. We firstly profiled gene expression of PTC cells after silencing of MAZ. . BRAF, , KRAS and LOC547 were identified as important target genes of TF MAZ. In particular, TF MAZ bound to the promoters of BRAF or KRAS and significantly increased their transcription and expression levels. Meanwhile, MAZ could noticeably elevate LOC547 transcription and expression as a TF. High levels of LOC547 relocated ACTN4 protein from the nucleus to the cytosol, improved protein-protein interactions between ACTN4 and EGFR in the cytosol, enhanced ERK1/2 phosphorylation, activated the MAPK signaling and, thus, promoted PTC progression. Our data identify a previously underappreciated MAZ-controlled transcriptional reprogram and ERK1/2 activation via BRAF, , KRAS and LOC547. . Our data illustrate that activation of the MAZ-controlled axis promotes thyroid tumorigenesis. These insights would advance our knowledge of the role of TFs in cancer development and highlight the potential of TFs as future targets for treatments against cancers.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Downregulation of Talin1 promotes hepatocellular carcinoma progression through activation of the ERK1/2 pathway
    Chen, Peijuan
    Lei, Ling
    Wang, Jian
    Zou, Xuejing
    Zhang, Dongyan
    Deng, Ling
    Wu, Dehua
    CANCER SCIENCE, 2017, 108 (06) : 1157 - 1168
  • [2] CircPDIA4 Induces Gastric Cancer Progression by Promoting ERK1/2 Activation and Enhancing Biogenesis of Oncogenic circRNAs
    Shen, Yue
    Zhang, Nasha
    Chai, Jie
    Wang, Teng
    Ma, Chi
    Han, Linyu
    Yang, Ming
    CANCER RESEARCH, 2023, 83 (04) : 538 - 552
  • [3] Tissue transglutaminase-2 promotes gastric cancer progression via the ERK1/2 pathway
    Wang, Xiaofeng
    Yu, Zhenjia
    Zhou, Quan
    Wu, Xiongyan
    Chen, Xuehua
    Li, Jianfang
    Zhu, Zhenggang
    Liu, Bingya
    Su, Liping
    ONCOTARGET, 2016, 7 (06) : 7066 - 7079
  • [4] hMAGEA2 promotes progression of breast cancer by regulating Akt and Erk1/2 pathways
    Park, Song
    Sung, Yonghun
    Jeong, Jain
    Choi, Minjee
    Lee, Jinhee
    Kwon, Wookbong
    Jang, Soyoung
    Park, Si Jun
    Kim, Hyeng-Soo
    Lee, Mee-Hyun
    Kim, Dong Joon
    Liu, Kangdong
    Kim, Sung-Hyun
    Dong, Zigang
    Ryoo, Zae Young
    Kim, Myoung Ok
    ONCOTARGET, 2017, 8 (23) : 37115 - 37127
  • [5] Tissue tranglutaminase-2 promotes gastric cancer progression via ERK1/2 pathway
    Su, Liping
    Wang, Xiaofeng
    Zhou, Quan
    Wu, Xiongyan
    Liu, Bingya
    CANCER RESEARCH, 2016, 76
  • [6] The serine protease CORIN promotes progression of gastric cancer by mediating the ERK1/2 MAPK pathway
    Hong, Runqi
    Zhang, Xiaotian
    Zhang, Yi
    Bei, Lanxin
    Yang, Ju
    Xia, Jie
    Hu, Zhiqing
    Cao, Zhipeng
    Chen, Rui
    Chen, Liang
    Niu, Gengming
    Ke, Chongwei
    MOLECULAR CARCINOGENESIS, 2024, 63 (08) : 1500 - 1514
  • [7] Transcriptional activation of ANO1 promotes gastric cancer progression
    Zeng, Xiaoqing
    Pan, Duyi
    Wu, Hao
    Chen, Hao
    Yuan, Wei
    Zhou, Ji
    Shen, Zhenbin
    Chen, Shiyao
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2019, 512 (01) : 131 - 136
  • [8] Role of Erk1/2 activation in prion disease pathogenesis: Absence of CCR1 leads to increased Erk1/2 activation and accelerated disease progression
    LaCasse, Rachel A.
    Striebel, James F.
    Favara, Cynthia
    Kercher, Lisa
    Chesebro, Bruce
    JOURNAL OF NEUROIMMUNOLOGY, 2008, 196 (1-2) : 16 - 26
  • [9] SGK2 promotes renal cancer progression via enhancing ERK 1/2 and AKT phosphorylation
    Liu, Y.
    Chen, J. -B.
    Zhang, M.
    Zhang, X. -L.
    Meng, J. -L.
    Zhou, J.
    Hao, Z. -Y.
    Zhang, L.
    Zu, X. -B.
    Liang, C. -Z.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2019, 23 (07) : 2756 - 2767
  • [10] KDM2A promotes lung tumorigenesis by epigenetically enhancing ERK1/2 signaling
    Wagner, Klaus W.
    Alam, Hunain
    Dhar, Shilpa S.
    Giri, Uma
    Li, Na
    Wei, Yongkun
    Giri, Dipak
    Cascone, Tina
    Kim, Jae-Hwan
    Ye, Yuanqing
    Multani, Asha S.
    Chan, Chia-Hsin
    Erez, Baruch
    Saigal, Babita
    Chung, Jimyung
    Lin, Hui-Kuan
    Wu, Xifeng
    Hung, Mien-Chie
    Heymach, John V.
    Lee, Min Gyu
    JOURNAL OF CLINICAL INVESTIGATION, 2013, 123 (12): : 5231 - 5246